SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus

Core Viewpoint - Marinus Pharmaceuticals is facing a federal securities class action lawsuit due to alleged misleading statements regarding the RAISE trial, which has led to significant stock price declines and investor losses [1][11]. Group 1: Legal Actions and Investor Impact - Faruqi & Faruqi, LLP is investigating claims against Marinus and has set an August 5, 2024 deadline for investors to seek lead plaintiff status in the class action [1]. - The stock price of Marinus fell by $0.14, or 8.91%, closing at $1.43 on May 8, 2024, following the announcement of the class action [2]. - The lawsuit alleges that Marinus executives made false statements regarding the risks associated with the RAISE trial, leading to investor damages when the truth was revealed [11]. Group 2: Stock Performance and Company Announcements - On April 15, 2024, Marinus announced that the RAISE trial did not meet early stopping criteria and would implement cost-saving measures, resulting in a stock price drop of $6.22, or 82.7%, closing at $1.30 [12]. - Following the April announcement, the stock further declined by $0.10, or 7.69%, to close at $1.20 on April 16, 2024 [12]. - On May 8, 2024, Marinus filed a Form 8-K with the SEC, announcing cost-cutting measures and the cessation of the Phase 3 RAISE II trial, which was influenced by the RAISE trial's results [13].